Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death. However, there is very limited knowledge on disease pathophysiology and host-virus interactions explaining the large interindividual variability in the course of hepatitis D. In a highly competitive call for proposals, the D-SOLVE consortium (“Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D”) has received four-year funding of 6.75 million euros from the Horizon 2020 EU Horizon Call „Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2)“ of the European Union for an unbiased screening of a large multicenter cohort of well-defined HDV-infected patients to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments. Hannover Medical School (MHH) with its Department of Gastroenterology, Hepatology and Endocrinology and its Centre for Individualised Infection Medicine (CiiM), a joint institution of MHH and the Helmholtz Centre for Infection Research (HZI) in Braunschweig, coordinates this international endeavor including institutions from Germany, France, Italy, Sweden and Romania.